Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

SABCS 2017

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.

Related Items

Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

Final Results of NeoMONARCH: A Phase 2 Neoadjuvant Study of Abemaciclib in Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

A Phase 1b Study of Abemaciclib plus Pembrolizumab for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

US Treatment Patterns for Young Women with HR-Positive, HER2-Negative Metastatic Breast Cancer in the Era of CDK4/6 Inhibitors

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

Phase 1-2 Trial of Pembrolizumab and Either Doxorubicin or an Aromatase Inhibitor for Triple-Negative or HR-Positive Metastatic Breast Cancer

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

Abemaciclib plus Standard Adjuvant ET versus Standard Adjuvant ET Alone in High-Risk Breast Cancer

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

The Synergistic Antitumor Activity of Entinostat (MS-275) in Combination with Palbociclib (PD 0332991) in ER-Positive and TN Breast Cancer

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

Abemaciclib for the Treatment of Brain Metastases Secondary to HR-Positive Breast Cancer

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

Phase 2 Study of the Feasibility and Safety of Radium-223 Dichloride plus Hormonal Therapy and Denosumab for the Treatment of HR-Positive Breast Cancer with Bone-Dominant Metastasis

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017

The Benefit of Abemaciclib in Prognostic Subgroups: An Exploratory Analysis of Combined Data from MONARCH 2 and 3

San Antonio Breast Cancer Symposium (SABCS)

SABCS 2017